44 centralized collection varieties have begun to renew their contracts, and more than one billion varieties such as acarbose, parecoxib, and pantoprazole have entered and retreated.

Beginning on April 26, an inter-provincial alliance led by Henan, including 13 provinces and municipalities including Shanxi, Inner Mongolia, Hubei, Hunan, Guangxi, Hainan, Chongqing and Qinghai, plans to conduct 44 second, second, The four batches of medicines for which the agreement for the centralized purchase of medicines with quantity of medicines has expired were organized by the state to carry out centralized purchase of medicines with quantity of medicines

According to the announcement, these 44 varieties mainly involve oral regular-release, sustained-release and controlled-release and injections, covering many common chronic diseases and diseases mainly based on drug treatment

The "1+N" pattern raises the difficulty of selecting large varieties

In the list of products renewed by the alliance of 13 provinces, autonomous regions and municipalities this time, parecoxib is one of the major varieties that the industry is more concerned about.

From the perspective of terminal data, the market share of this large variety is being reshaped: the domestic market of parecoxib continues to expand, and the terminal sales of Chinese public medical institutions in 2020 will exceed 2 billion yuan, a year-on-year increase of 10.

The current situation is that the original manufacturer Pfizer's parecoxib injection plus 30 domestic pharmaceutical companies have been approved to produce parecoxib sodium for injection, of which 27 have been reviewed, including Kelun Pharmaceutical, Chia Tai Tian Qing, Hengrui, Buchang Pharmaceutical,

As far as the pattern is concerned, the top five market share of this variety in 2020 are: Pfizer 43.

In fact, facing the same choice is pantoprazole

In the list, there are many similar large varieties, and it has been less than a week for enterprises to choose to test their strategic decision-making ability

Renewal is imminent, Bayer, Luye and Hengrui have opportunities

The reporter noticed that a number of common chronic disease drugs were included in the list
.
Among them, acarbose is a commonly used hypoglycemic drug in clinical practice
.
According to data from Minet.
com, in recent years, China's online pharmacy terminal diabetes chemical drug market has expanded year by year, and it will be close to 1 billion yuan in 2021, a year-on-year increase of 95.
32%
.
And in 2021, the total market share of the TOP10 products of Chinese online pharmacy terminal diabetes drugs will exceed 70%, and the market share of the top three dapagliflozin tablets, metformin hydrochloride tablets, and acarbose tablets will all exceed 10%
.

In the previous second batch of national procurement, the bidding companies for acarbose included Sino-US Huadong, Luye Pharma and Bayer, a subsidiary of Huadong Medicine
.
Among them, Bayer won the right to choose acarbose (50mg) with a drop of 78% and a low price of 0.
18 yuan per tablet, which became the biggest explosion point of the second batch of national procurement
.
According to the data, 14 companies have passed the consistency evaluation of generic drugs, and there is 1 original drug company
.
It is conceivable that in the second and fourth batch of national procurement renewals, acarbose will still face fierce bidding
.

Clinically, the medicines for respiratory system diseases are mainly cough-relieving, expectorant-relieving and asthma-relieving drugs
.
According to data from Minet.
com, the sales of respiratory system chemicals in China's online pharmacies have grown rapidly in recent years, and will exceed the 1 billion yuan mark in 2021, a year-on-year increase of nearly 70%
.
Among the second and fourth batches of nationally adopted and renewed varieties, the commonly used clinical expectorant ambroxol is also on the list
.

In addition to the original research pharmaceutical company Boehringer Ingelheim, there are currently many varieties of ambroxol hydrochloride in the market .
According to the data, in August 2018, Hengrui's ambroxol tablets were the first to be reviewed.
Shandong Yuxin, Changzhou four Consistency evaluation has been conducted on oral preparations of Pharma, Shanxi Qianyuan and Shanghai Xinyi Balance
.
As of September 2020, 232 production approvals for ambroxol have been approved in China
.
According to statistics, in the first quarter of 2020, domestic public hospitals in key provinces and cities accounted for 53% of domestic ambroxol, and 47.
08% of original research drugs
.
Among them, Changzhou Siyao and Chenxin Pharmaceutical have a relatively high proportion of domestic production
.

According to the product renewal rhythm of the first and third batches of provinces/alliances, some experts predict that the volume of submissions will be published next.
It is expected that the draft of the continuation rules and the official shortlisting rules will be published in May, and then the alliance's renewal bids and quotations will be released.
The results of the alliance's bid renewal will be announced, and it is expected that the results of the bid renewal will be implemented in July
.

Text editor: Chen Shuwen

Format editor: Chen Shuwen